GnRH Agonist Mechanism of Action
GnRH agonists initially stimulate pituitary gonadotrophs causing a transient surge in LH and FSH secretion, followed by receptor downregulation that leads to profound suppression of the hypothalamic-pituitary-gonadal axis—this paradoxical suppression after initial stimulation is the primary therapeutic mechanism. 1, 2
Initial Stimulatory Phase
GnRH agonists bind to G protein-coupled receptors on pituitary gonadotroph cells with greater potency and longer half-life than native GnRH 2, 3. This binding triggers:
- Phosphoinositide breakdown generating inositol 1,4,5-trisphosphate (IP3) and diacylglycerol 2
- Calcium mobilization from intracellular stores 2, 4
- Protein kinase C activation 2, 5
- Immediate gonadotropin secretion (LH and FSH) with subsequent gonadal response 1, 3
Desensitization and Downregulation Phase
Prolonged GnRH receptor activation causes desensitization and receptor downregulation, which is the therapeutic goal 1, 2. This results in:
- Suppressed gonadotropin secretion (LH and FSH levels become insufficient to maintain gonadal function) 6, 1
- Hypogonadal state with decreased sex steroid production 1
- Regression of sex characteristics in pubertal suppression (breast atrophy in girls, decreased testicular volume in boys) 1
Clinical Manifestations by Population
In transgender adolescents, GnRHa therapy halts pubertal development—breast development becomes atrophic and menses stop in natal females; virilization stops and testicular volume decreases in natal males 1.
In women with functional hypothalamic amenorrhea, the mechanism involves reduced GnRH drive manifesting as reduced LH pulse frequency, though this represents the pathophysiology rather than therapeutic use 6.
In central precocious puberty, GnRHa effectively suppresses premature HPG axis activation 7.
Key Clinical Distinction from Antagonists
GnRH antagonists immediately suppress gonadotropin secretion by competitive receptor blockade without any initial stimulatory phase, making them fundamentally different from agonists 2, 3. Antagonists avoid the initial "flare" effect but require continuous administration as no long-acting formulations are widely available 1.
Reversibility
GnRH agonist effects are completely reversible—discontinuation leads to immediate resumption of spontaneous pubertal development and restoration of the pituitary-gonadal axis 1, 3. This reversibility is a major advantage over alternative suppressive agents like high-dose progestins.
Molecular Signaling Cascade
The receptor-mediated actions involve 8, 4, 5:
- Activation of phospholipase D and A2
- Arachidonic acid metabolite production
- Calcium-calmodulin pathway activation
- Mitogen-activated protein kinase (MAPK) signaling
- Complex crosstalk between multiple messenger molecules mediating diverse GnRH actions
The therapeutic utility exploits the paradoxical suppression that occurs after the initial stimulation—this is why agonists require several weeks to achieve full suppression, unlike antagonists which work immediately.